Similar articles

• Immunotherapy and chemoimmunotherapy of malignant disease with BCG and nonviable mycobacterial fractions.

  Schwarz MA, Gutterman JU, Hersh EM, Richman SP, Mavligit GM. Schwarz MA, et al. World J Surg. 1977 Sep;1(5):555-83. doi: 10.1007/BF01556181. World J Surg. 1977. PMID: 272083 No abstract available.
• BCG and cancer.

  Bast RC Jr, Zbar B, Borsos T, Rapp HJ. Bast RC Jr, et al. N Engl J Med. 1974 Jun 27;290(26):1458-69. doi: 10.1056/NEJM197406272902605. N Engl J Med. 1974. PMID: 4598691 Review. No abstract available.
• BCG as adjuvant immunotherapy for neoplasia.

  Hersh EM, Gutterman JU, Mavligit GM. Hersh EM, et al. Annu Rev Med. 1977;28:489-515. doi: 10.1146/annurev.me.28.020177.002421. Annu Rev Med. 1977. PMID: 324372 Review. No abstract available.
• [Immunotherapy of cancer: evolution of concepts and clinical advances].

  Baldwin RW. Baldwin RW. Rev Prat. 1980 Jan 21;30(5):221-4, 227-8. Rev Prat. 1980. PMID: 6929557 French. No abstract available.
• [Immunotherapy of cancer with BCG].

  Yamamura Y, Azuma I. Yamamura Y, et al. Nihon Rinsho. 1974 Mar;32(3):542-53. Nihon Rinsho. 1974. PMID: 4603604 Review. Japanese. No abstract available.